Jamieson, Liz http://orcid.org/0000-0002-3667-0423
Harrop, Emily http://orcid.org/0000-0002-2480-2062
Liossi, Christina http://orcid.org/0000-0003-0627-6377
Boyce, Katherine
Mitchell, Lorraine
Johnson, Margaret
Jani, Yogini http://orcid.org/0000-0001-5927-5429
Akinyooye, Victoria
Skene, Simon S. http://orcid.org/0000-0002-7828-3122
Wong, Ian C. K. http://orcid.org/0000-0001-8242-0014
Howard, Richard F. http://orcid.org/0000-0001-9271-0074
Oulton, Kate http://orcid.org/0000-0002-5778-3849
Funding for this research was provided by:
Research for Patient Benefit Programme (PB-PG-0317-20036, PB-PG-0317-20036, PB-PG-0317-20036, PB-PG-0317-20036, PB-PG-0317-20036, PB-PG-0317-20036, PB-PG-0317-20036, PB-PG-0317-20036, PB-PG-0317-20036, PB-PG-0317-20036, PB-PG-0317-20036)
Article History
Received: 8 December 2021
Accepted: 28 March 2022
First Online: 17 May 2022
Declarations
:
: NHS Research Ethics Committee and Health Research Authority (HRA) approval was obtained prior to the start of the study (IRAS project id: 252624/ REC reference 19/LO/0765) and from local committees/ R&D departments in participating centres. All methods were carried out in accordance with relevant guidelines and regulations. Written informed consent was obtained from the participants and parents in the case of minors.
: Not applicable.
: ICKW is the founder of Therakind Ltd which was funded by Wockhardt Pharmaceutical to conduct the clinical studies for Ayendi® (diamorphine hydrochloride) licensing application. All other authors declare that they have no completing interests.